Current Wegovy evidence
The injection label reports a small mean increase and larger maximum changes in some adults
The June 18, 2026 Wegovy label says treatment was associated with increased resting heart rate. In adult weight-reduction trials, the mean increase with Wegovy injection was 1 to 4 beats per minute compared with placebo. Maximum changes from baseline at any visit of 10 to 19 beats per minute occurred in 41% of injection-treated adults versus 34% with placebo, while changes of 20 beats per minute or more occurred in 26% versus 16%. Those maximum-change percentages do not mean the increase was continuous, do not establish an arrhythmia rate, and do not predict one patient’s resting pulse.
- Keep the figures tied to the Wegovy injection trial population, placebo comparison, and current manufacturer label rather than presenting them as a class-wide semaglutide rate.
- The label says findings were similar in a Wegovy tablet trial, but it does not provide the same adult percentage breakdown there; do not invent or transfer tablet-specific percentages.
- Wegovy labeling advises regular heart-rate monitoring, reporting palpitations or a racing heartbeat at rest, and discontinuation if a sustained resting-heart-rate increase occurs; the prescriber should interpret and act on that instruction.
Ozempic and tablet evidence
Other labeled semaglutide products report different product-specific averages
The June 1, 2026 manufacturer Ozempic injection label reports that 0.5 mg and 1 mg doses produced a mean heart-rate increase of 2 to 3 beats per minute in placebo-controlled trials, while placebo produced a mean decrease of 0.3 beats per minute. The January 30, 2026 combined Ozempic and Rybelsus tablet label reports a mean increase of 1 to 3 beats per minute with the studied 7 mg and 14 mg semaglutide tablets and no change with placebo. These data come from different products, routes, doses, labels, and trial contexts, so they are not a head-to-head ranking and should not be averaged together.
- Confirm the brand, route, strength, indication, package, and current manufacturer set before quoting a heart-rate figure.
- A small group-average increase does not prove that semaglutide caused one episode of palpitations, and it does not rule out a clinically important change in an individual.
- Do not treat a cardiovascular label indication as proof that a specific new pulse or rhythm symptom is harmless or that semaglutide treats an arrhythmia.
What else can affect pulse
Fluid loss, low glucose, medicines, and other conditions can overlap with semaglutide care
A fast, pounding, fluttering, or irregular heartbeat during semaglutide treatment can have more than one possible contributor. Vomiting, diarrhea, low intake, dehydration, fever, pain, anxiety, caffeine, nicotine, alcohol, stimulants, decongestants, thyroid medicine, anemia, infection, and heart-rhythm or thyroid conditions can affect pulse or symptom perception. Low blood sugar deserves particular review when semaglutide is combined with insulin or a sulfonylurea. These possibilities are a differential checklist, not a way to diagnose the cause at home.
- Record the pulse and symptoms at rest, after standing, after activity, around meals, and during gastrointestinal illness only as directed; include glucose or blood-pressure readings when the care plan calls for them.
- Share fainting history, known arrhythmia, heart or thyroid disease, anemia, sleep apnea, pregnancy possibility, recent illness, and all prescriptions, over-the-counter products, supplements, caffeine, nicotine, and alcohol.
- Do not self-treat a persistent fast pulse with extra fluids, electrolytes, caffeine avoidance alone, a beta blocker, or a semaglutide dose change without individualized medical guidance.
Product and formulation identity
Branded trial findings do not establish the rate for compounded semaglutide
Wegovy and Ozempic are FDA-approved branded semaglutide products with presentation-specific prescribing information. A patient-specific compounded semaglutide preparation is not FDA-approved Wegovy, Ozempic, or a generic equivalent and can differ in concentration, inactive ingredients, additives, container, pharmacy directions, storage, and beyond-use date. A symptom review should verify the dispensing pharmacy and actual label rather than assuming a branded trial rate applies to a compounded vial or additive formulation.
- Bring the prescription label, product name, route, concentration or strength, pharmacy, prescriber, ingredients, refill or lot details, storage history, and a photo of the current container.
- If vitamin B12, NAD+, MIC, or another additive is listed, review the final formulation and every ingredient; do not assume an additive prevents heart-rate effects or makes the preparation an FDA-approved combination product.
- Avoid research-use semaglutide, unlabeled vials, counterfeit pens or tablets, copied syringe charts, no-prescription checkout, and sellers that hide the dispensing pharmacy.
Monitoring and escalation
There is no universal online pulse cutoff for changing treatment
A meaningful response depends on the person’s usual resting pulse, the size and persistence of the change, symptoms, rhythm regularity, hydration and glucose context, other medicines, and cardiovascular history. The current Wegovy label uses the phrase sustained increase rather than giving one universal patient-facing number. Contact the prescriber with the actual trend and symptoms rather than relying on a generic cutoff or wearable alert alone. Severe symptoms should bypass portal messaging and refill support for urgent in-person care.
- Ask which device and resting-measurement method to use, how often to check, what change should trigger same-day contact, and when an ECG, laboratory testing, medication review, or local examination is appropriate.
- Do not skip, repeat, split, stop, restart, switch route, or change concentration based on one reading or an online dosing chart.
- Seek urgent evaluation for chest pain, fainting, severe shortness of breath, confusion, new weakness or speech difficulty, a sustained severe racing or irregular heartbeat with symptoms, or another rapidly worsening pattern.